The BioHub - by Avetix

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We’re joined by Joe Payne, CEO and founder of Arcturus Therapeutics. Joe has been instrumental in pushing the boundaries of mRNA technology, leading Arcturus to develop one of the first self-amplifying mRNA COVID-19 vaccines and pioneering new treatments for diseases like cystic fibrosis. In this episode, Joe shares his journey, the ground breaking work at Arcturus, and his vision for the future of RNA medicine. Let’s dive in! Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. I’m pleased to introduce Adrian Rawcliffe, CEO of Adaptimmune Therapeutics. With over 20 years of experience in the pharmaceutical and biotech industries, Adrian has led pivotal roles at GSK and now spearheads the development of breakthrough T-cell therapies at Adaptimmune, tackling some of the toughest challenges in cancer and beyond. We’re excited to dive into Adrian’s journey, the advancements at Adaptimmune, and what the future holds for T-cell therapies. Welcome to the show, Adrian! Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of hosting Greg Kunst, CEO of Aurion Biotech. Greg is a seasoned leader in the biotech industry with a remarkable career spanning drug development, commercialization, and market access. At Aurion, Greg has driven the company to incredible heights, raising over $200 million and securing product approval in Japan for their groundbreaking cell therapy platform. Under his leadership, Aurion has grown rapidly, with operations expanding across the U.S. and Japan. In this episode, we’ll explore Greg’s journey from his extensive experience in the industry to taking the helm at Aurion, the innovative technologies driving their mission, and what the future holds for this cutting-edge biotech company. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We’re thrilled to have Sophia Lugo, CEO and co-founder of Radar Therapeutics. Sophia’s journey from El Paso to leading Radar is truly inspiring. Her passion for medicine and public health drives her mission to bring representation and accessibility to mRNA therapies. Radar Therapeutics is pioneering precision-expressed mRNAs to target specific diseased cells, aiming to revolutionize treatments for conditions like cancer and rare diseases. Recently, Radar raised $13.4 million in seed funding to advance their groundbreaking work. In this episode, we’ll explore Sophia’s journey, the technology behind Radar, and the importance of health equity in medicine. Enjoy and stay tuned.

Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David-Alexandre "DA" Gros, a seasoned leader in the biotech industry and the current CEO & Director of Eledon Pharmaceuticals. DA's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO Imbria Pharmaceuticals, President and Chief Operating Officer of Neurocrine Biosciences, Chief Business and Principal Financial Officer at Alynlam Pharmaceuticals, Chief Strategy Officer and EVP, Strategy & Business Development at Sanofi, Principal, Healthcare Investment Banking at Centerview Partners & Vice President, Healthcare Investment Banking at Merrill Lynch. Now, at the helm of Eledon Pharmaceuticals, Eledon are focused on striving to both extend the functional life of transplanted organs and reduce side effects of current immunosuppressive treatments such as kidney toxicity, high blood pressure, and tremor. DA's deep expertise, from startups to larger pharmaceutical companies gives him a unique perspective on how to steer innovative science towards tangible clinical outcomes. We're excited to dive into his journey, the challenges and successes along the way, changing career lanes & the business development landscape.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.We are thrilled to have Charmaine Lykins, Commercial Strategy Advisor at MapLight Therapeutics, join us. Charmaine brings over 25 years of extensive experience in the commercial sector of psychiatry and neurology. Prior to MapLight, she was the Commercial Strategy Advisor at Karuna Therapeutics, where she spearheaded the commercial capabilities for the launch of KarXT in schizophrenia and Alzheimer's disease psychosis.Charmaine's impressive career includes commercial strategy and execution for 10 product launches in the US and globally for CNS indications.In this episode, we’ll dive into the resurgence of interest in neuro and CNS disorders, the importance of involving commercial teams early in development, and the challenges and rewards of bringing new treatments to market.Enjoy and stay tuned

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of speaking with Laurent Audoly. Laurent is the co-founder and CEO of PriveBio, a precision medicine biotech focused on tackling metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases. Having had roles at Pfizer, Merck, Kymera Therapeutics, and more, Laurent has been instrumental in bringing several novel medicines to market, including 9 through IND and helping 100’s of thousands of patients. He has also successfully led multiple biotech startups. Join us as we delve into Laurent's journey, the challenges he has faced, and his vision for the future of PriveBio and the biotech industry. Enjoy and stay tuned.

Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Ravneesh Sachdev, a seasoned leader in the biotech industry and the currently partner and Head of Business Development at Apple Tree Partners. Ravneesh experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as SVP Head of Business Development at Acceleron, VP Head of Business Development at Sage Therapeutics, VP Business Development at Bioveritav and Executive Director Business Development at Acorda Therapeutics.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We have the pleasure of speaking with Laurent Audoly. Laurent is the co-founder and CEO of PriveBio, a precision medicine biotech focused on tackling metabolic dysfunction and fibro-inflammation in cardiorenal metabolic diseases. Having had roles at Pfizer, Merck, Kymera Therapeutics, and more, Laurent has been instrumental in bringing several novel medicines to market, including 9 through IND and helping 100’s of thousands of patients. He has also successfully led multiple biotech startups. Join us as we delve into Laurent's journey, the challenges he has faced, and his vision for the future of PriveBio and the biotech industry. Enjoy and stay tuned.

Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry. We're thrilled to welcome Doug Love, the dynamic President and Chief Executive Officer of Annexon Biosciences. With a storied career that spans over two decades in biotech, Douglas brings a wealth of experience from his transformative roles at companies like Elan Pharmaceuticals and Genentech. At Annexon, he's at the helm of pioneering treatments for classical complement-mediated disorders, driving forward innovations that promise to change the lives of patients around the globe. Join us as Douglas shares his journey through the biotech landscape, the challenges and achievements of leading Annexon, and his vision for the future of medical treatments. Enjoy and stay tuned.